Cellectis plans a Phase 1 investigator-initiated trial (IIT) in China, with preliminary clinical data expected in the second half of 2027. CLLS closed Tuesday at $1.05, up 8.64%.

Cellectis announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate ...

ProJenX, a clinical-stage biotechnology company developing novel, targeted, brain-penetrant therapies for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, ...

Large language model pretraining optimizes a neural network on vast token sequences so it learns reusable linguistic, factual ...

APOC3 in a single administration76% triglyceride reduction after a single dose in murine disease modelNEW YORK, Oct.

Lamassu Biotech today announced initial safety and pharmacokinetic data from the ongoing first-in-human Phase 1/2a clinical trial (LB-SA53-101) of SA53, an oral MDM2 inhibitor, at the European Society ...

October 26, 2026) - BCM Resources Corporation (TSXV: B) ("BCM" or the "Company") is pleased to announce that recently completed geophysical surveys are beginning to highlight new prospective targets ...

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human ...

Learn seven design patterns for data science code, from Strategy and Adapter to Command and Proxy, each matched to the ...

Data poisoning manipulates training, fine-tuning, evaluation, or retrieval data so an AI system learns corrupted behavior or ...

Hugging Face's Carbon-X AI model lets researchers analyze DNA using natural language, with lower reported costs and local deployment options for labs.

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...